The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties.
Amino-anthranilic acid derivatives have been identified as a new class of low serum shifted, high affinity full agonists of the human orphan G-protein-coupled receptor GPR109a with improved ADME properties.